Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial

BACKGROUND: CFI-400945 is a first-in-class oral inhibitor of polo-like kinase 4 (PLK4) that regulates centriole duplication. Primary objectives of this first-in-human phase 1 trial were to establish the safety and tolerability of CFI-400945 in patients with advanced solid tumours. Secondary objectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Veitch, Zachary W., Cescon, David W., Denny, Trisha, Yonemoto, Lisa-Maria, Fletcher, Graham, Brokx, Richard, Sampson, Peter, Li, Sze-Wan, Pugh, Trevor J., Bruce, Jeffrey, Bray, Mark R., Slamon, Dennis J., Mak, Tak W., Wainberg, Zev A., Bedard, Philippe L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738068/
https://www.ncbi.nlm.nih.gov/pubmed/31303643
http://dx.doi.org/10.1038/s41416-019-0517-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738068/
https://www.ncbi.nlm.nih.gov/pubmed/31303643
http://dx.doi.org/10.1038/s41416-019-0517-3

Ejemplares similares